Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Impact of adaptation algorithm, timing, and stopping boundaries on the performance of Bayesian response adaptive randomization in confirmative trials with a binary endpoint.

Jiang Y, Zhao W, Durkalski-Mauldin V.

Contemp Clin Trials. 2017 Nov;62:114-120. doi: 10.1016/j.cct.2017.08.019. Epub 2017 Sep 1.


Clinical Evaluation of the Patient With Acute Stroke.

Southerland AM.

Continuum (Minneap Minn). 2017 Feb;23(1, Cerebrovascular Disease):40-61. doi: 10.1212/CON.0000000000000437. Review.


Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury.

Jha RM, Puccio AM, Chou SH, Chang CH, Wallisch JS, Molyneaux BJ, Zusman BE, Shutter LA, Poloyac SM, Janesko-Feldman KL, Okonkwo DO, Kochanek PM.

Crit Care Med. 2017 Mar;45(3):e255-e264. doi: 10.1097/CCM.0000000000002079.


ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI.

Jha RM, Puccio AM, Okonkwo DO, Zusman BE, Park SY, Wallisch J, Empey PE, Shutter LA, Clark RS, Kochanek PM, Conley YP.

Neurocrit Care. 2017 Apr;26(2):213-224. doi: 10.1007/s12028-016-0309-z.


Suspected Large Vessel Occlusion: Should Emergency Medical Services Transport to the Nearest Primary Stroke Center or Bypass to a Comprehensive Stroke Center With Endovascular Capabilities?

Southerland AM, Johnston KC, Molina CA, Selim MH, Kamal N, Goyal M.

Stroke. 2016 Jul;47(7):1965-7. doi: 10.1161/STROKEAHA.115.011149. Epub 2016 Feb 19. No abstract available.


The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.

Connor JT, Broglio KR, Durkalski V, Meurer WJ, Johnston KC.

Trials. 2015 Mar 4;16:72. doi: 10.1186/s13063-015-0574-8.


Managing competing demands in the implementation of response-adaptive randomization in a large multicenter phase III acute stroke trial.

Zhao W, Durkalski V.

Stat Med. 2014 Oct 15;33(23):4043-52. doi: 10.1002/sim.6213. Epub 2014 May 22.


The effect of covariate adjustment for baseline severity in acute stroke clinical trials with responder analysis outcomes.

Garofolo KM, Yeatts SD, Ramakrishnan V, Jauch EC, Johnston KC, Durkalski VL.

Trials. 2013 Apr 11;14:98. doi: 10.1186/1745-6215-14-98.


Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.

Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, Dillon C, Elm J, Lindblad A, Morgenstern L, Poisson SN, Palesch Y.

Int J Stroke. 2013 Aug;8(6):479-83. doi: 10.1111/ijs.12129.


The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke.

Bruno A, Durkalski VL, Hall CE, Juneja R, Barsan WG, Janis S, Meurer WJ, Fansler A, Johnston KC; SHINE investigators.

Int J Stroke. 2014 Feb;9(2):246-51. doi: 10.1111/ijs.12045. Epub 2013 Mar 19.


Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

Southerland AM, Johnston KC.

Ann N Y Acad Sci. 2012 Sep;1268:72-8. doi: 10.1111/j.1749-6632.2012.06731.x. Review.

Supplemental Content

Loading ...
Support Center